Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000810320 | SCV000950514 | benign | Nemaline myopathy 2 | 2024-02-19 | criteria provided, single submitter | clinical testing | |
Gene |
RCV002285415 | SCV002575959 | likely benign | not provided | 2019-02-05 | criteria provided, single submitter | clinical testing | See Variant Classification Assertion Criteria. |
Revvity Omics, |
RCV002285415 | SCV003810149 | uncertain significance | not provided | 2022-03-31 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV004800599 | SCV005422376 | uncertain significance | not specified | 2024-10-11 | criteria provided, single submitter | clinical testing | Variant summary: NEB c.24201T>G (p.Asn8067Lys) results in a non-conservative amino acid change in the encoded protein sequence. Three of four in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 4.9e-05 in 143952 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. To our knowledge, no occurrence of c.24201T>G in individuals affected with Nemaline Myopathy 2 and no experimental evidence demonstrating its impact on protein function have been reported. ClinVar contains an entry for this variant (Variation ID: 654368). Based on the evidence outlined above, the variant was classified as uncertain significance. |
Natera, |
RCV000810320 | SCV001454439 | uncertain significance | Nemaline myopathy 2 | 2020-01-17 | no assertion criteria provided | clinical testing |